
Sylentis’ pipeline is directed towards indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases.
********************

ECCO : EUROPEAN CROHN,S AND COLITIS ORGANISATION .
EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB .